NIOX Group PLC (NIOX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NIOX Group PLC (NIOX) has a cash flow conversion efficiency ratio of 0.130x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX8.80 Million ≈ $1.07K USD) by net assets (GBX67.60 Million ≈ $8.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NIOX Group PLC - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how NIOX Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of NIOX Group PLC for a breakdown of total debt and financial obligations.
NIOX Group PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NIOX Group PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Poddar Housing and Development Limited
NSE:PODDARHOUS
|
0.838x |
|
Hochdorf Holding AG
SW:HOCN
|
-0.550x |
|
Zaplox AB
ST:ZAPLOX
|
25.961x |
|
Century Global Commodities Corp
TO:CNT
|
-0.047x |
|
Techfast Holdings Bhd
KLSE:0084
|
-0.008x |
|
NuGen Medical Devices Inc
V:NGMD
|
0.122x |
|
Superior Mining International Corp
V:SUI
|
0.002x |
|
Group 107 Ltd
TA:G107
|
-0.133x |
Annual Cash Flow Conversion Efficiency for NIOX Group PLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of NIOX Group PLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see NIOX Group PLC market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX67.60 Million ≈ $8.22K |
GBX15.80 Million ≈ $1.92K |
0.234x | -19.15% |
| 2024-12-31 | GBX59.50 Million ≈ $7.24K |
GBX17.20 Million ≈ $2.09K |
0.289x | +108.83% |
| 2023-12-31 | GBX83.80 Million ≈ $10.20K |
GBX11.60 Million ≈ $1.41K |
0.138x | 0.00% |
| 2023-12-30 | GBX83.80 Million ≈ $10.20K |
GBX11.60 Million ≈ $1.41K |
0.138x | +69.21% |
| 2022-12-31 | GBX81.90 Million ≈ $9.96K |
GBX6.70 Million ≈ $815.20 |
0.082x | 0.00% |
| 2022-12-30 | GBX81.90 Million ≈ $9.96K |
GBX6.70 Million ≈ $815.20 |
0.082x | +290.34% |
| 2021-12-31 | GBX66.80 Million ≈ $8.13K |
GBX1.40 Million ≈ $170.34 |
0.021x | 0.00% |
| 2021-12-30 | GBX66.80 Million ≈ $8.13K |
GBX1.40 Million ≈ $170.34 |
0.021x | +105.80% |
| 2020-12-31 | GBX66.10 Million ≈ $8.04K |
GBX-23.90 Million ≈ $-2.91K |
-0.362x | 0.00% |
| 2020-12-30 | GBX66.10 Million ≈ $8.04K |
GBX-23.90 Million ≈ $-2.91K |
-0.362x | -22.16% |
| 2019-12-31 | GBX84.80 Million ≈ $10.32K |
GBX-25.10 Million ≈ $-3.05K |
-0.296x | 0.00% |
| 2019-12-30 | GBX84.80 Million ≈ $10.32K |
GBX-25.10 Million ≈ $-3.05K |
-0.296x | -33.41% |
| 2018-12-31 | GBX183.00 Million ≈ $22.27K |
GBX-40.60 Million ≈ $-4.94K |
-0.222x | 0.00% |
| 2018-12-30 | GBX183.00 Million ≈ $22.27K |
GBX-40.60 Million ≈ $-4.94K |
-0.222x | -43.13% |
| 2017-12-31 | GBX371.60 Million ≈ $45.21K |
GBX-57.60 Million ≈ $-7.01K |
-0.155x | 0.00% |
| 2017-12-30 | GBX371.60 Million ≈ $45.21K |
GBX-57.60 Million ≈ $-7.01K |
-0.155x | +14.54% |
| 2016-12-31 | GBX312.60 Million ≈ $38.03K |
GBX-56.70 Million ≈ $-6.90K |
-0.181x | 0.00% |
| 2016-12-30 | GBX312.60 Million ≈ $38.03K |
GBX-56.70 Million ≈ $-6.90K |
-0.181x | -43.32% |
| 2015-12-31 | GBX440.90 Million ≈ $53.64K |
GBX-55.80 Million ≈ $-6.79K |
-0.127x | 0.00% |
| 2015-12-30 | GBX440.90 Million ≈ $53.64K |
GBX-55.80 Million ≈ $-6.79K |
-0.127x | +34.56% |
| 2014-12-31 | GBX190.80 Million ≈ $23.21K |
GBX-36.90 Million ≈ $-4.49K |
-0.193x | 0.00% |
| 2014-12-30 | GBX190.80 Million ≈ $23.21K |
GBX-36.90 Million ≈ $-4.49K |
-0.193x | +67.50% |
| 2013-12-31 | GBX30.05 Million ≈ $3.66K |
GBX-17.88 Million ≈ $-2.18K |
-0.595x | 0.00% |
| 2013-12-30 | GBX30.05 Million ≈ $3.66K |
GBX-17.88 Million ≈ $-2.18K |
-0.595x | -- |
About NIOX Group PLC
NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled N… Read more